chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Fri. Apr. 23, 2021: Within 12 hours of vaccine administration, and in addition to injection site soreness and discomfort, began to notice tenderness above left clavicle, and could feel slight lump or swelling there.  Sat. Apr. 24, 2021:  -7am-8am. Lump on upper surface and tucked behind left clavicle more noticeable and tender, painful if pressed.  Was often irritated and pressed on by seatbelt when driving.   -8pm: Lump above and on clavicle a noticeably swollen, firm mass approximately 2cm across, painful to pressure or touch.  Apparently a swollen lymph node.   Injection site deltoid sore, like ?punch? to arm.  From this point on I will not document that further, other than to say the soreness peaked the following day, and lessened to non-issue rapidly after.  Sun. Apr. 25, 2021: -8am: Swollen lymph node above left clavicle swollen even more, 2-2.5cm across, constantly sore.  Painful when touched or pressed. -12pm: Pain associated with swollen lymph node above left clavicle spread laterally to lateral end of clavicle, and slight swelling to discomfort below lateral end of clavicle, in hollow between pectoral and deltoid muscles.  Remained through night.  Mon. Apr. 26, 2021: -8am: Lymph node over left clavicle still enlarged and tender, painful to touch or pressure, but not quite as bad as previous day. Irritated by seatbelt when driving. -8pm: Lymph node over left clavicle reduced in size to around 1.5cm across, still firm to touch and painful when pressed.    Tue. Apr. 27, 2021: -8am: Lymph node still swollen, about 1-1.5cm across, firm, and painful if pressed.   -8pm: Lymph node approximately 1cm across, but still firm, and painful if pressed.    Wed. Apr. 28, 2021: -8am: Lymph node above left clavicle remains approximately 1cm in size, firm to touch, but not painful, only some tenderness if pressed. -8pm: Same condition as earlier in day.  Thurs. Apr. 29, 2021 through Fri. May 7, 2021:  The lymph node above the left clavicle was pain free.  It stayed the same size, around 1cm, and is still firm enough to feel and locate by touch.  May 7 marked 2 weeks since vaccination dose 1.  Please note, patient was diagnosed as Covid-19 positive on Dec. 27 or 28th, 2020, but had a nearly symptom-free run of the disease (slight and short-lived cough, some joint pain 1 day, no fever, no other symptoms).
Symptoms: Chills, fever up to 39.2° Celsius, severe pain in left arm, body ache, headache, severe fatigue.   Treatment: Only rest. No medication recommendation by primary care provider.   Outcome: Symptoms improved with 1-2 days, and were gone by the 3rd day.
This spontaneous report was received from a licensed nursing practitioner refers to a 19 year old female patient. No relevant medical history of the patient was reported. The patient on 02-MAY-2002, 30-MAY-2002 and 12-DEC-2002 received unspecified Hepatitis B vaccine (manufacturer unknown) (lot number, expiry date, strength and route of administration were unknown). Thimerosal content was unknown. There were no concomitant medications reported. It was reported that the patient had indeterminate antibodies for Hepatitis B, as detected by a test on an unspecified date. The reporting nurse did not have the lot numbers of the unspecified Hepatitis B vaccine (manufacturer unknown) because they were administered at another practice. On 18-NOV-2014 the patient was vaccinated with an adult dose of RECOMBIVAX HB lot # J008227, expiry date 07-FEB-2016 (strength and route of administration were unknown), rather that the pediatric dose for which she was indicated. Thimerosal content was unknown. There were no concomitant medications reported. The patient experienced no adverse effects at this time. There was no product quality complaint involved. The outcome and causality for the event had indeterminate antibodies for Hepatitis B was unknown. Additional information has been requested.
24 hours after receiving the vaccine I became dizzy with nausea; almost feels like motion sickness.  Taking Zofran every 4 hours for the past three days, not helping.
Headache, tingling in right hand, fatigue, Hematoma to injection site with redness. Took Tylenol helped with the headache. Currently on symptoms are fatigue and the hematoma at the injection site with redness, other symptoms have resolved.
Per phone call into office patient developed a rash on upper arm, flu-like symptoms fatigue and abdominal pain for 3 days.
Pt (6 of 6) reports post vaccine developed fever, inconsolable crying and swelling and induration at injection site that was hot to touch.
Patient noticed a rash on her torso on Friday evening that seemed to be resolving on its own by Saturday.
Narrative: Pt was vaccinated with Pfizer mRNA vaccine on 3-11-21 and 3-31-21. There was no specific info in any note regarding reaction other than swelling of the arm listed in allergies. Pt was vaccinated again in same arm for second dose with no mention of recurring reaction.
On 5/10/99, the pt developed a mild rash with fever. By 5/11/99, the rash had manifested into a "full blown" body rash with a fever of 104F. Also, the pt experienced photophobia. It was noted that "the parents are going to bring child into the physician's office today". According to the reporter, the physician expressed concern with the vaccine lot. As stated by the reporter, "this is not the first case of this occurring with this physician and she doesn't want to use anymore of the MMRII stock that she has of this lot due to this occurrence. She suspects that this lot may have a high titer". At the time of the report, the pt's rash and fever persisted. Additional information on the progress of the pt was received. It was indicated that the pt recovered from symptoms within 3 days. No further details were provided.
The symptoms were similar but not as intense as those when he had the original vaccination on 07/05/2010. The new symptoms started about seven days after the vaccination. Sleeping, the high pitched crying, discomfort, loss of appetite, but was just not himself a change in personality, and had some seizures or tremors on the night of 07/14/2010.
Area around injection site extremely red, swollen, sore to touch and complains of discomfort to move arm.
Per patient's  most recent visit note:   Patient and her mom have similar sx.  it started 3 days after a recent covid (pfizer) shot, the 2nd one.  Patient has intense pain at the site of the shot (right arm0, but also pain in the left arm.  the right arm pain shoots down her arm and she can't straighten her elbow because of it.  She has a tremor of the hand especially the little finger.   She has swelling around the eyes and generalized joint pain  This all began 3 days after the shot, and she and her mom attribute it to the vaccine. Patient was diagnosed in infancy as having a neural crest disorder.  i am not clear from the history whether the vaccine is reportedly exascerbating this neural crest disorder.  She is otherwise a normal teen.
Information has been received from a health professional concerning a 12 year old female who on 10-Nov-2007 was vaccinated intramuscularly in the upper thigh with the third dose of Gardasil (lot number not provided).  On 10-Nov-2007 the patient developed a knot that was hot, red, tender to the touch, and about the size of a half dollar.  No further information is available.
Patient developed varicella lesions over trunk and back ranging from erythematous macules to vesicles.
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose12/23/21 2nd dose01/11/21 Diagnosed covid positive:08/18/21 Symptom onset:08/15/21 Exposure:Travel Symptoms:cough, fatigue,loss of smell/taste, sorethroat,HA
Resting heart rate of 105 bpm with palpitations lasting the last 17 hours.; Resting heart rate of 105 bpm with palpitations lasting the last 17 hours.; Off label use; A third (booster) dose of BNT162b2 was administered; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 21Oct2021 at 08:45 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included influenza vaccine (MANUFACTURER UNKNOWN) taken on 09Oct2021 for an unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 02Feb2021 at 08:15 (at the age of 36-years-old) as a single dose for COVID-19 immunisation and received the second dose BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 24Feb2021 at 08:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient received flu vaccine within four weeks prior to the COVID-19 vaccine. On 21Oct2021 at 20:15, the patient experienced resting heart rate of 105 beats per minute (bpm) with palpitations lasting the last 17 hours. On 21Oct2021, the patient underwent lab test which included heart rate test and the result was 105 bpm. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events resting heart rate of 105 bpm with palpitations lasting the last 17 hours was resolved on 22Oct2021.   The lot number for BNT162b2 was not provided and will be requested during follow up.
HEADACHE, NAUSEA, CHILLS, DIARRHEA, PAIN AND SWELLING AT INJECTION SITE
Pt felt faint and started to sweat after receiving the vaccine. We laid him down on a flat surface with his feet up for a few minutes. Used wet towels and ice packs to cool him down.  Felt better after a few minutes and was able to sit at ' post vaccination site'. After a few more minutes he stated that he wasn't feeling 'good' and so laid him down again and called 911 who then came ad took care of him. Called  him after 7 pm , spoke with him and he stated that he was feeling fine.
On an unknown date, the patient experienced covid.; On an unknown date, the patient experienced covid.; FACILITATED COLLECT  This is a solicited report received from contactable reporter(s) (Consumer or other non HCP) for a sponsored program. The reporter is the patient. Other Case identifier(s): 22K-163-4245037-00.  A 22 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administration date 05Sep2021 (Batch/Lot number: unknown) at the age of 22 years as dose 3 (booster), single for covid-19 immunisation; adalimumab (HUMIRA), subcutaneous (Batch/Lot number: unknown) for ankylosing spondylitis. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (1st dose, Route of Admin: Intramuscular), administration date: 15Mar2021, when the patient was 22 years old, for COVID-19 Immunization, reaction(s): "COVID-19", "COVID-19"; Bnt162b2 (2nd dose, Route of Admin: Intramuscular), administration date: 15May2021, when the patient was 22 years old, for COVID-19 Immunization, reaction(s): "COVID-19", "COVID-19", "On 15Mar2021, he received 1st doseCovid-19 Vaccine/05May2021, patient received 2nd dose Covid-19 Vaccine".  The following information was reported: COVID-19 (medically significant), outcome "recovering", DRUG INEFFECTIVE (medically significant), outcome "unknown" and all described as "On an unknown date, the patient experienced covid.". The action taken for adalimumab was unknown. The reporter considered "on an unknown date, the patient experienced covid." related to bnt162b2.  Causality for HUMIRA (ADALIMUMAB)  The reporters causality for the event(s) of COVID with HUMIRA(ADALIMUMAB) was no reasonable possibility.  Causality for PFIZER BIONTECH COVID-19 VACCINE (TOZINAMERAN)  The reporters causality for the event(s) of COVID with PFIZER BIONTECH COVID-19 VACCINE (TOZINAMERAN)  was possible.  The lot number for bnt162b2 was not provided and will be requested during follow up.; Sender's Comments: Based on known drug safety profile, there is reasonable possibility of causal association between the events  COVID-19, DRUG INEFFECTIVE and the suspect drug BNT162B2.
Lymph nodes in left arm extremely painful for ~4 days which required ibuprofen to be taken along with left axillary that lasted ~2.5 weeks.
Very sore shoulder with limited movement.  For 4 days, pain and movement improved but it still hurts when I move my arm.  The vaccine was very painful going in; like it had never hurt that bad.  Shot seemed a little high, and my arm was bent not straight.  I feel like I have a tendentious flare up.  I may need a cortisone shot if it does not get better.
No adverse event; Monovalent vaccine was administered to a child after date of expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Monovalent vaccine was administered to a child after date of expiry) and NO ADVERSE EVENT (No adverse event) in a 4-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AS1412B) for COVID-19 prophylaxis.     It was unknown whether the patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.     On 07-Mar-2023, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Mar-2023,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Monovalent vaccine was administered to a child after date of expiry). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Monovalent vaccine was administered to a child after date of expiry) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Monovalent vaccine was administered to a child after date of expiry).    No concomitant medications were provided. No treatment medication was provided.
On 2/14/17 - TDAP was administered to the (R) upper deltoid - IM. On 2/17/17 - Employee reported with tenderness, redness, rash to lower (mid) Rt. forearm, no respiratory symptoms. On 2/21/17 - she calls, reported that she went to the ER for worsening symptoms - including generalized rashes, aches.
Initial and follow-up information has been received from a physician concerning a 73 year old female patient, whose reported weight was 135 pounds and whose reported height was 62 inches with hypertension who 7 years ago, approximately in the year 2000 was vaccinated intramuscularly in the left arm with Pneumovax 23 (reportedly with no reaction reported then).  On 03-JAN-2007 the patient was vaccinated intramuscularly with another dose of Pneumovax 23 (Lot # 651329/1047P).  On 03-JAN-2007, that evening, the patient reported an injection site reaction.  The physician reported the patient developed swelling and redness from the injection site, which was in her upper arm to her elbow.  On 04-JAN-2007, the patient went to the Emergency Room (ER) because the reaction worsened and was started on KEFLEX for possible cellulitis reaction.  The patient was not admitted.  The physician also reported that one week before the vaccine was administered, the product was left at room temperature for 48 hours.  At the time of the report, the patient had recovered, and also reported as "AE" not improved.  In follow-up it was reported by the physician that the patient had "probable cellulitis" from the site of vaccination (upper arm) just above the elbow, which began 24 hours after vaccination and resolved 3-4 days later.  The patient recovered on 08-JAN-2007.  Additional information has been requested.
Red circle about the size of a half dollar less than 24 hrs after shot and then went to about 4 to 5 inches long and 3 to 4 inches wide after 48 hours.  Started running a fever.   Started taking antibiotics and put hydrocortisone cream on the spot.
FATIGUE, PAIN IN ARM FOR 2 DAYS, STIFF NECK 4 DAYS, HEADACHE STILL TODAY, VOMITING.
Information has been received from a physician concerning a patient who was vaccinated with a dose of varicella virus vaccine live (Oka/Merck). Subsequently the patient developed chickenpox. It was unknown if medical attention was sought. The patient's outcome was not reported. Additional information has been requested.
Patient was inadvertently administered first dose of Moderna vaccine.  Second dose administered April 26, 2021 per CDC guidelines and parental consent given.
Alopecia areata; Hair still falling out.; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 57-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 07Apr2022 as dose 4 (booster), single (Lot number: FJ6369) at the age of 57 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Eczema, allergies, now non-manifest." (unspecified if ongoing); "known allergies: Latex" (unspecified if ongoing); "known allergies: penicillin" (unspecified if ongoing); "known allergies: beta lactam antibiotics" (unspecified if ongoing), notes: known allergies: beta lactam antibiotics; "allergies, now non-manifest" (unspecified if ongoing). Concomitant medication(s) included: VITAMIN C [ASCORBIC ACID]; VITAMIN D [COLECALCIFEROL]. Vaccination history included: Covid-19 vaccine (Dose: 03 , Manufacturer unknown), for COVID-19 Immunization; Covid-19 vaccine (Dose: 02, Manufacturer unknown), for COVID-19 Immunization; Covid-19 vaccine (Dose: 01, Manufacturer unknown), for COVID-19 Immunization. The following information was reported: ALOPECIA AREATA (non-serious) with onset 10May2022, outcome "not recovered"; ALOPECIA (non-serious) with onset 10May2022, outcome "not recovered", described as "Hair still falling out.". The events "alopecia areata" and "hair still falling out." required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of alopecia areata, alopecia.  Additional information: The most recent COVID-19 vaccine was administered at Workplace clinic. Alopecia areata commenced (first noticed) approximately 4-5 weeks later, now increased to large areas of back and sides of scalp. Hair still falling out. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Other medications the patient received within 2 weeks of vaccination included Vitamin C, vitamin D. Events were treated with Acupuncture. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19 with negative nasal swab result.
PATIENT STATED THAT SHE WAS FINE IMMEDIATELY FOLLOWING VACCINE BUT THE NEXT DAY WAS VERY ILL AND VOMITING 10 TIMES. SHE DROVE HERSELF TO HOSPITAL TO GET IV TREATMENT FOR DEHYDRATION.
Pt received influenza vaccine to R thigh. Localized swelling and redness and pain to R thigh noticed the next day. Improved today after Benadryl and Ibuprofen.
His allergies are really bad; This is a spontaneous report from a contactable consumer via the Pfizer-sponsored program. A male patient of an unspecified age received his first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date at a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported.  The patient experienced his allergies are really bad on an unspecified date. The outcome of the event was unknown.  Information on the lot/batch number has been requested.
Apr 14: 1 inch diameter bright red and raised area formed where shot was given. Temp 99.2, generalized achiness, chills, & fatigue. Apr 15: 2.25 inch diam. cherry red and indurated area at vaccine site. The site was approx. 1/4 inch raised. Temp 98.8 and site very painful & hot. Apr 16: 2.5 inch diameter maroon and even more indurated at site, hard and painful. Apr 17: redness subsided minimally. Apr 18: redness and induration minimally receded. Apr 19 - present: Sl. pink but palpable induration at vaccination site. I took pictures every day. Redness resolved however 3" diameter palpable "knot" persists.
Blurring of vision; Posssibly silent migraine; Blind spot in vision; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 20Apr2021 at 17:45 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 30Mar2021 at 05:45 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. On 22Apr2021 at 08:00, the patient experienced blurring of vision, blind spot in vision and possibly silent migraine. The events resulted in doctor or other healthcare professional office or clinic visit. Since the vaccination, the patient had not been tested for COVID-19. It was unknown whether therapeutic measures were taken as a result of the reported events. The clinical outcome of the events blurring of vision, blind spot in vision and possibly silent migraine were unknown at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Site: Pain at Injection Site-Mild, Systemic: Dizziness / Lightheadness-Mild, Systemic: Fainting / Unresponsive-Mild, Systemic: Felt light-headed, and fell unresponsive for less then 1 minute-Mild, Systemic: Flushed / Sweating-Mild, Additional Details: called 911, EMT/paramedics came, checked vitals (all were fine), Blood glucose 100.
Painful Lymphadenopathy on day 6 post vaccination, not present prior to day 5, localized to axilla on the same side as vaccination; This is a spontaneous report from a contactable nurse (patient). A 33-year-old female patient received first dose of  BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EL0140; expiry date: unknown) via an unspecified route of administration (left arm), on 30Dec2020 at 07:15 a.m., at a single dose, for COVID-19 immunization. The patient's medical history was not reported. Concomitant medication included an unspecified birth control. The patient previously took amoxicillin and experienced allergies. The patient is not pregnant at the time of vaccination. The patient was not diagnosed with COVID prior vaccination. The patient did not receive other vaccines within four weeks prior to COVID vaccination. The vaccine was administered in the hospital. On 04Jan2021, at 07:00 a.m., the patient experienced painful lymphadenopathy on day 6 post vaccination, not present prior to day 5, localized to axilla on the same side as vaccination. The patient did not receive treatment for the event. Outcome of the event was unknown.